MXPA03003481A - Treatment of sexual dysfunction using bombesin antagonist. - Google Patents

Treatment of sexual dysfunction using bombesin antagonist.

Info

Publication number
MXPA03003481A
MXPA03003481A MXPA03003481A MXPA03003481A MXPA03003481A MX PA03003481 A MXPA03003481 A MX PA03003481A MX PA03003481 A MXPA03003481 A MX PA03003481A MX PA03003481 A MXPA03003481 A MX PA03003481A MX PA03003481 A MXPA03003481 A MX PA03003481A
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
bombesin antagonist
bombesin
antagonist
Prior art date
Application number
MXPA03003481A
Other languages
Spanish (es)
Inventor
Herman Thijs Stock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA03003481A publication Critical patent/MXPA03003481A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females.
MXPA03003481A 2000-11-17 2000-11-17 Treatment of sexual dysfunction using bombesin antagonist. MXPA03003481A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/004380 WO2002040022A1 (en) 2000-11-17 2000-11-17 Treatment of sexual dysfunction using bombesin antagonist

Publications (1)

Publication Number Publication Date
MXPA03003481A true MXPA03003481A (en) 2004-09-10

Family

ID=9886325

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003481A MXPA03003481A (en) 2000-11-17 2000-11-17 Treatment of sexual dysfunction using bombesin antagonist.

Country Status (13)

Country Link
EP (1) EP1333829A1 (en)
JP (1) JP2004525864A (en)
KR (1) KR20040062416A (en)
CN (1) CN1479618A (en)
AU (1) AU2001214046A1 (en)
BR (1) BR0017374A (en)
CA (1) CA2426521A1 (en)
HU (1) HUP0303500A2 (en)
IL (1) IL155814A0 (en)
MX (1) MXPA03003481A (en)
PL (1) PL366002A1 (en)
WO (1) WO2002040022A1 (en)
ZA (1) ZA200303250B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123163A1 (en) 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituted cyclohexane-1,4-diamine derivatives
US7244743B2 (en) 2002-06-05 2007-07-17 Solvay Pharmaceuticals Gmbh Non-peptidic BRS-3 agonists
CN117665174B (en) * 2024-02-01 2024-04-23 巴中市产品质量检验检测中心 Method for detecting PDE5 and SSRI and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5650395A (en) * 1995-03-13 1997-07-22 Hurel; Steven Treatment of pulmonary hypertension
BR9711342A (en) * 1996-08-22 1999-08-17 Warner Lambert Co Non-peptide bombesin receptor antagonists
JP2002533338A (en) * 1998-12-18 2002-10-08 ワーナー−ランバート・カンパニー Non-peptide NK1 receptor antagonist
AU4825200A (en) * 1999-05-07 2000-11-21 Board Of Regents, The University Of Texas System Oral steroidal hormone compositions and methods of use
DE69904025T2 (en) * 1999-06-04 2003-07-31 Jordanian Pharmaceutical Mfg A Condensed pyrimidine derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
WO2002040022A1 (en) 2002-05-23
EP1333829A1 (en) 2003-08-13
AU2001214046A1 (en) 2002-05-27
JP2004525864A (en) 2004-08-26
BR0017374A (en) 2003-09-30
IL155814A0 (en) 2003-12-23
PL366002A1 (en) 2005-01-24
CA2426521A1 (en) 2002-05-23
ZA200303250B (en) 2004-04-26
KR20040062416A (en) 2004-07-07
CN1479618A (en) 2004-03-03
HUP0303500A2 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
MXPA03003482A (en) Treatment of sexual dysfunction.
BG103510A (en) Nasal ready-made forms for the treatment of sexual disorders
IL146003A0 (en) USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
PT1135153E (en) USES FOR ANTAGONISTS AND AGNISTS OF EPH RECEPTORS FOR TREATING VASCULAR DISORDERS
MXPA03004915A (en) Mch antagonists and their use in the treatment of obesity.
IL144007A0 (en) Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
IL153492A0 (en) Treatment of male sexual dysfunction
MY127234A (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
IL141235A0 (en) Combined use of an alpha-adrenoceptor antagonist and amuscarinic antagonist in the treatment of benign prostatic hyperplasi
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
MXPA02009904A (en) Apomorphine derivatives and methods for their use.
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
MXPA03003481A (en) Treatment of sexual dysfunction using bombesin antagonist.
MXPA03004547A (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction.
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
ATE230265T1 (en) COMPOSITION OF ALPHA-ADRENERGIC ANTAGONISTS WITH NITROGEN OXIDE DONORS FOR THE TREATMENT OF SEXUAL FUNCTION DISORDERS IN WOMEN
EP1395593A4 (en) Novel pyrazolopyrimidinethione derivatives. preparation methods thereof and their use as therapeutics for erectile dysfunction
GB2423029A (en) Penis erection-enhancing device and methods of use thereof
EP1508337A3 (en) Uses for eph receptor antagonists and agonists to treat vascular disorders
GB0222931D0 (en) Improvements in and relating to the treatment of erectile dysfunction
MY155220A (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
SI1173178T1 (en) Composition comprising apomorphine and sildenafil and the use thereof for the treatment of erectile dysfunction
MXPA02010115A (en) Enhanced compositions for the treatment of male erectile dysfunction.